Lea Dutta
Overview
Explore the profile of Lea Dutta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
1055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Makker V, Taylor M, Aghajanian C, Cohn A, Brose M, Di Simone C, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38242717
Background: Lenvatinib plus pembrolizumab demonstrated clinically meaningful benefit in patients with previously treated advanced endometrial carcinoma in Study 111/KEYNOTE-146 (NCT02501096). In these exploratory analyses from this study, we evaluated the...
2.
Makker V, Aghajanian C, Cohn A, Romeo M, Bratos R, Brose M, et al.
J Clin Oncol
. 2023 Jan;
41(5):974-979.
PMID: 36608305
JCO The open-label phase Ib/II Study 111/KEYNOTE-146 of daily lenvatinib 20 mg plus pembrolizumab 200 mg once every 3 weeks showed promising efficacy and tolerable safety in patients with previously...
3.
Yonemori K, Yunokawa M, Ushijima K, Sakata J, Shikama A, Minobe S, et al.
Cancer Sci
. 2022 May;
113(10):3489-3497.
PMID: 35612971
Study 309/KEYNOTE-775 is a phase 3 open-label, randomized trial of lenvatinib plus pembrolizumab versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer with progression after platinum-based therapy....
4.
Makker V, Colombo N, Casado Herraez A, Santin A, Colomba E, Miller D, et al.
N Engl J Med
. 2022 Jan;
386(5):437-448.
PMID: 35045221
Background: Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. Methods: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced...
5.
Gaspar N, Venkatramani R, Hecker-Nolting S, Gallego Melcon S, Locatelli F, Bautista F, et al.
Lancet Oncol
. 2021 Aug;
22(9):1312-1321.
PMID: 34416158
Background: Tyrosine kinase inhibitors have shown activity in osteosarcoma and might enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 dose and antitumour activity of lenvatinib...
6.
Makker V, Taylor M, Oaknin A, Casado Herraez A, Orlowski R, Dutta L, et al.
Oncologist
. 2021 Jun;
26(9):e1599-e1608.
PMID: 34190370
Background: The combination of lenvatinib plus pembrolizumab has shown efficacy in treatment of advanced endometrial carcinoma (that is not microsatellite instability-high or mismatch repair deficient) following prior systemic therapy in...
7.
Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T, et al.
N Engl J Med
. 2021 Feb;
384(14):1289-1300.
PMID: 33616314
Background: Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear. Methods: In...
8.
Grunwald V, Powles T, Choueiri T, Hutson T, Porta C, Eto M, et al.
Future Oncol
. 2019 Jan;
15(9):929-941.
PMID: 30689402
Aim: Lenvatinib plus everolimus is approved for the treatment of advanced renal cell carcinoma (RCC) after one prior vascular endothelial growth factor-targeted therapy. Lenvatinib plus pembrolizumab demonstrated promising antitumor activity...